Short answer
Compass Therapeutics, Inc. (CMPX) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$18M
- −10.1% YoY
- EPS (diluted)
- −$0.10
- +16.7% YoY
Source: XBRL data from the Compass Therapeutics, Inc. (CMPX) Q1 2026 10-Q on SEC EDGAR. USD.
Compass Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales generated
- Net loss $18.3M vs $16.6M YoY; operating loss $20.3M vs $18.0M
- Tovecimig highest R&D spending at $5.5M; CTX-8371 lowest at $1.3M
- Operating cash use $17.3M vs $13.2M YoY; cash, equivalents and securities $195M
- Funding expected into 2028; additional capital required for development and commercialization needs
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Carried-forward business, financial, operational, regulatory, and competitive risks remain applicable
- No newly triggered regulatory, legal, compliance, liquidity, debt, currency, or concentration risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Compass Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.